Skip to main content

Advertisement

SpringerLink
Log in

Immunosuppressive therapy for myelodysplastic syndromes: Refining the indications

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Myelodysplastic syndromes (MDS) are often associated with autoimmune processes that contribute to the cytopenias that characterize this disease group. Ten years ago, several investigators described improvement in the cytopenia of MDS following immunosuppressive treatments (IST) with antithymocyte globulin or cyclosporine. These findings have since been widely confirmed. The consensus is that about 30% of unselected transfusion-dependent patients with MDS given IST have sustained hematologic responses and can regain transfusion independence. Over the past decade, prognostic features have been defined that accurately identify the subset of patients most likely to benefit from IST. With increasing knowledge about the pathophysiology of myelosuppression in MDS, we are beginning to define the immunosuppressive agents and schedules with the greatest chance of causing hematologic improvement. Significantly, long-term follow-up indicates that IST responders have a better progression-free survival than comparable patients with MDS who do not receive IST.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Barrett J, Saunthararajah Y, Molldrem J: Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000, 37:15–29.

    Article  PubMed  CAS  Google Scholar 

  2. Barrett AJ, Sloand E, Young NS: Immunological mechanisms and treatment of MDS. In Myelodysplastic Syndromes: Clinical and Biological Advances. Edited by Greenberg PL. New York: Cambridge University Press; 2006.

    Google Scholar 

  3. Chen G, Zheng W, Miyazato A: Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 2004, 104:4210–4218.

    Article  PubMed  CAS  Google Scholar 

  4. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, et al.: Hematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T cell receptor Vbeta profiles. Br J Haematol 1998, 102:1314–1322.

    Article  PubMed  CAS  Google Scholar 

  5. Young NS, Barrett AJ: Perspective: the treatment of severe acquired aplastic anemia. Blood 1995, 85:3367–3377.

    PubMed  CAS  Google Scholar 

  6. Jonasova A, Neuwirtova R, Cermak J, et al.: Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998, 100:304–309.

    Article  PubMed  CAS  Google Scholar 

  7. Molldrem JJ, Caples M, Mavroudis DA, et al.: Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997, 99:699–705.

    Article  PubMed  CAS  Google Scholar 

  8. Sloand EM, Mainwaring L, Fuhrer M, et al.: Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005, 106:841–851.

    Article  PubMed  CAS  Google Scholar 

  9. Shimamoto T, Tohyama K, Okamoto T, et al.: Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leuk Res 2003, 27:783–788.

    Article  PubMed  CAS  Google Scholar 

  10. Atoyebi W, Bywater L, Rawlings L, et al.: Treatment of myelodysplasia with oral cyclosporin. Clin Lab Haematol 2002, 24:211–214.

    Article  PubMed  CAS  Google Scholar 

  11. Scheinberg P, Fischler S, Li L, et al.: Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 2007, 109:3219–3224.

    Article  PubMed  CAS  Google Scholar 

  12. Molldrem JJ, Leifer E, Bahceci E, et al.: Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002, 137:156–163.

    PubMed  Google Scholar 

  13. Aivado M, Rong A, Stadler M, et al.: Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a ‘non-clonal’ pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol 2002, 68:210–216.

    Article  PubMed  CAS  Google Scholar 

  14. Steensma DP, Dispenzieri A, Moore SB, et al.: Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 2003, 101:2156–2158.

    Article  PubMed  CAS  Google Scholar 

  15. Stadler M, Germing U, Kliche JO, et al.: A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004, 18:460–465.

    Article  PubMed  CAS  Google Scholar 

  16. Yazji S, Giles J, Tsimberidou AM, et al.: Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 2003, 17:2101–2106.

    Article  PubMed  CAS  Google Scholar 

  17. Killick SB, Mufti G, Cavenagh JD, et al.: A pilot study of anti-thymocyte globulin (ATG) in the treatment of patients with ‘low-risk’ myelodysplasia. Br J Haematol 2003, 120:679–684.

    Article  PubMed  CAS  Google Scholar 

  18. Deeg HJ, Jiang PY, Holmberg LA, et al.: Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res 2004, 28:1177–1180.

    Article  PubMed  Google Scholar 

  19. Sloand EM, Greenberg P, Wu C, et al.: Immunosuppressive treatment is associated with durable responses and a survival advantage in younger patients with int-1 myelodysplastic syndrome [abstract]. Blood 2005, 106(Suppl 1). Abstract 2519.

    Google Scholar 

  20. Melchert M, Kale V, List A: The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Curr Opin Hematol 2007, 14:123–129.

    Article  PubMed  CAS  Google Scholar 

  21. Saunthararajah Y, Nakamura R, Nam JM, et al.: HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002, 100:1570–1574.

    PubMed  CAS  Google Scholar 

  22. Saunthararajah Y, Nakamura R, Wesley R, et al.: A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003, 102:3025–3027.

    Article  PubMed  CAS  Google Scholar 

  23. Greenberg P, Cox C, LeBeau MM, et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079–2088.

    PubMed  CAS  Google Scholar 

  24. Barrett AJ, Savani BN: Allogeneic stem cell transplantation for myelodysplastic syndrome. Semin Hematol 2007, In press.

  25. Barrett AJ, Rezvani K: Translational mini-review series on vaccines: peptide vaccines for myeloid leukaemias. Clin Exp Immunol 2007, 148:189–198.

    Article  PubMed  CAS  Google Scholar 

  26. Rezvani K, Yong A, Mielke S, et al.: Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2007, In press.

Download references

Author information

Authors and Affiliations

  1. Room 3-5330, Clinical Research Center, National Heart, Lung, and Blood Institute, 10 Center Drive, Bethesda, MD, 20892, USA

    A. John Barrett

Authors
  1. A. John Barrett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elaine M. Sloand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. John Barrett.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barrett, A.J., Sloand, E.M. Immunosuppressive therapy for myelodysplastic syndromes: Refining the indications. Curr Hematol Malig Rep 3, 23–28 (2008). https://doi.org/10.1007/s11899-008-0005-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-008-0005-y

Keywords

Search

Navigation